Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press73510.17650/2222-1468-2022-12-1-35-52DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORSДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ ГОЛОВЫ И ШЕИRational sequence of monoclonal antibodies in the treatment of non-resectable head and neck squamous cell carcinomaРациональная последовательность моноклональных антител в лечении нерезектабельного плоскоклеточного рака головы и шеиhttps://orcid.org/0000-0003-4879-2687BolotinaL. V.БолотинаЛ. В.
Russian Federation

Larisa Vladimirovna Bolotina

Moscow

Л.В. Болотина

г. Москва

lbolotina@yandex.ruhttps://orcid.org/0000-0002-2061-0522UstinovaT. V.УстиноваТ. В.
Russian Federation

T. V. Ustinova

Moscow

Т.В. Устинова

г. Москва

https://orcid.org/0000-0002-3371-7548DеshkinaT. I.ДешкинаТ. И.
Russian Federation

T. I. Dеshkina

Moscow

Т. И. Дешкина

г. Москва

https://orcid.org/0000-0003-3532-6476GolubevP. V.ГолубевП. В.
Russian Federation

P. V. Golubev

Moscow

П. В. Голубев

г. Москва

LyubavinaN. N.ЛюбавинаН. Н.
Russian Federation

N. N. Lyubavina

Moscow

Н. Н. Любавина

г. Москва

FedenkoA. A.ФеденкоА. А.
Russian Federation

A. A. Fedenko

Moscow

А. А. Феденко

г. Москва

https://orcid.org/0000-0001-8784-8415KaprinA. D.КапринА. Д.
Russian Federation

A. D. Kaprin

Moscow

А. Д. Каприн

г. Москва

P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of RussiaМосковский научно-исследовательский онкологический институт им. П. А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииРeoples’ Friendship University of RussiaФГАОУ ВО «Российский университет дружбы народов»1904202212135521604202216042022Copyright ©; 2022, Bolotina L.V., Ustinova T.V., Dеshkina T.I., Golubev P.V., Lyubavina N.N., Fedenko A.A., Kaprin A.D.Copyright ©; 2022, Болотина Л.В., Устинова Т.В., Дешкина Т.И., Голубев П.В., Любавина Н.Н., Феденко А.А., Каприн А.Д.2022Bolotina L.V., Ustinova T.V., Dеshkina T.I., Golubev P.V., Lyubavina N.N., Fedenko A.A., Kaprin A.D.Болотина Л.В., Устинова Т.В., Дешкина Т.И., Голубев П.В., Любавина Н.Н., Феденко А.А., Каприн А.Д.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/735

This article discusses current approaches to first-line chemotherapy for non-resectable head and neck squamous cell carcinoma and describes factors affecting the choice of treatment regimen according to the results of randomized clinical trials. We provide a rationale for creating a long-term strategy of chemotherapy in different clinical situations. We also report two cases of concomitant administration of cetuximab and platinum-based therapy as an example of high efficacy of monoclonal antibodies.

В статье рассматриваются современные подходы к лекарственной терапии 1‑й линии нерезектабельного плоскоклеточного рака головы и шеи, а также описываются факторы, влияющие на выбор предпочтительного режима лечения и определенные на основе анализа результатов рандомизированных клинических исследований. Приводятся основания для выстраивания долгосрочной стратегии лекарственной терапии в различных клинических ситуациях. В качестве примера высокой эффективности моноклональных антител описываются 2 клинических наблюдения применения цетуксимаба в сочетании с платиносодержащей химиотерапией.

head and neck tumorschemotherapymonoclonal antibodiescetuximabimmunotherapyопухоли головы и шеихимиотерапиямоноклональные антителацетуксимабиммунотерапияPatterson R.H., Fischman V.G., Wasserman I. et al. Global burden of head and neck cancer: economic consequences, health, and the role of surgery. Otolaryngol Head Neck Surg 2020;162(3):296–303. DOI: 10.1177/0194599819897265.Joshi P., Dutta S., Chaturvedi P. et al. Head and neck cancers in developing countries. Rambam Maimonides Med J 2014;5(2):e0009. DOI: 10.5041/RMMJ.10143.Fagan J.J. Semon Lecture, Royal Society of Medicine: laryngectomy practice based on personal research. J Laryngol Otol 2021;135(7):E3. DOI: 10.1017/S0022215121001511.Fagan J.J., Zafereo M., Aswani J. et al. Head and neck surgical subspecialty training in Africa: sustainable models to improve cancer care in developing countries. Head Neck 2017;39(3):605–11. DOI: 10.1002/hed.24591.Kiong K.L., Guo T., Yao C.M.K.L. et al. Changing practice patterns in head and neck oncologic surgery in the early COVID-19 era. Head Neck 2020;42(6):1179–86. DOI: 10.1002/hed.26202.Patil V.M., Srikanth A., Noronha V. et al. The pattern of care in head-and-neck cancer: comparison between before and during the COVID-19 pandemic. Cancer Res Stat Treat 2020;3(Suppl S1):7–12.NCCN Guidelines Version 1.2021 Head and Neck Cancers. Avaliable at: www.nccn.org.Seiwert T.Y., Burtness B., Mehra R. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17(7):956–65. DOI: 10.1016/S1470-2045(16)30066-3.Cohen E.E.W., Soulières D., Le Tourneau C. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open- label, phase 3 study. Lancet 2019;393(10167):156–7. DOI: 10.1016/S0140-6736(18)31999-8.Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018;81:45–51. DOI: 10.1016/j.oraloncology.2018.Burtness B., Harrington K.J., Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915–28. DOI: 10.1016/S0140-6736(19)32591-7.Szturz P., Vermorken J.B. Translating KEYNOTE-048 into practice recommendations for head and neck cancer. Ann Transl Med 2020;8(15):975. DOI: 10.21037/atm.2020.03.164.Szturz P., Wouters K., Kiyota N. et al. Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice. Front Oncol 2019;9:464. DOI: 10.3389/fonc.2019.00464.Argiris A., Harrington K.J., Tahara M. et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Front Oncol 2017;7:72. DOI: 10.3389/fonc.2017.00072.Tahara M., Doi I., Murata T. et al. Re- challenge of platinum-based chemotherapy for platinum-refractory patients with recurrent or metastatic head and neck cancer: claims data analysis in Japan. JHEOR 2020;7(1):43–51. DOI: 10.36469/jheor.2020.12853.Guigay J., Tahara M., Licitra L. et al. The evolving role of taxanes in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: evidence, advantages, and future directions. Front Oncol 2019;9:668. DOI: 10.3389/fonc.2019.00668.Guigay J., Fayette J., Mesia R. et al. TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2020:38(15):6507. DOI: 10.1200/JCO.2020.38.15_suppl.6507.Burtness B., Harrington K.J., Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915–28. DOI: 10.1016/S0140-6736(19)32591–7Ferris R., Licitra L., Fayette J. et al. Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in checkmate 141 by prior cetuximab use. Clin Cancer Rese 2019;25(17):5221–30. DOI: 10.1158/1078-0432.Even C., Torossian N., Ibrahim T. et al. First line versus second line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2019;30(suppl_5):v449–74. DOI: 10.1093/annonc/mdz252.Dietz A., Welslau M., Hahn D. et al. Realworld outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany. J Clin Oncol 2020;38(15).Guigay J., Aupérin A., Fayette J. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicenter, openlabel, randomized, phase 2 trial. Lancet Oncol 2021;22(4):463–75. DOI: 10.1016/S1470-2045(20)30755-5.Saleh K., Daste A., Martin N. et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck. Eur J Cancer 2019;121:123–9. DOI: 10.1016/j.ejca.2019.08.026.European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Public Assessment Report, Keytruda, October 2019. Available at: https://www.ema.europa.eu/en/documents/variation-report/keytruda-hc-3820-ii-0065-epar-assessment-reportvariation_en.pdf.Sacco A.G., Chen R., Worden F.P. et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomized, multicenter, phase 2 trial. Lancet Oncol 2021;22(6):883–92. DOI: 10.1016/S1470-2045(21)00136-4.